预约演示
更新于：2026-08-26
Loxoprofen Sodium Hydrate
洛索洛芬钠
更新于：2026-08-26
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H22NaO5 |
InChIKeyDXWVOSJVYBPLND-UHFFFAOYSA-N |
CAS号226721-96-6 |
关联
177
项与 洛索洛芬钠 相关的临床试验CTR20263166
洛索洛芬钠贴剂在中国健康试验参与者外用条件下单次给药的人体生物等效性临床试验
JPRN-jRCTs071260057
A Study on the Efficacy of Haishu San and Antibiotics Administered Concurrently in Wound Healing During Periodontal Treatment -A Randomized Controlled Trial-
(A Study on the Efficacy of Haishu San and Antibiotics Administered Concurrently in Wound Healing During Periodontal Treatment
)
CTR20262120
洛索洛芬钠片在健康试验参与者中单中心、随机、开放、两制剂空腹/餐后生物等效性试验
100 项与 洛索洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 洛索洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 洛索洛芬钠 相关的专利（医药）
登录后查看更多信息
896
项与 洛索洛芬钠 相关的文献（医药）2026-09-01JOURNAL OF CONTROLLED RELEASE
Design of active pharmaceutical ingredient-ionic liquids for enhanced delivery to skin
Article
作者: Pérez-Cuevas, Mónica B ; Xu, Yuan ; Arslan Azizoglu, Gulcin ; Massey, Sarah ; Yang, Zhanhong ; Dani, Kunal ; Prausnitz, Mark R
Active pharmaceutical ingredient ionic liquids (API-ILs) can enhance skin delivery by tuning physicochemical properties based on ion-pair structure. We developed a four-step workflow to screen non-steroidal anti-inflammatory drug (NSAID)-based ion pairs formed by salt metathesis by (i) verifying IL formation using nuclear magnetic resonance spectroscopy, thermogravimetric analysis and differential scanning calorimetry; (ii) quantifying API-IL physicochemical properties relevant to skin transport, including drug concentration, molecular weight, aqueous solubility, and distribution coefficient; (iii) measuring API-IL skin permeation through pig skin ex vivo; and (iv) formulating API-ILs to reduce viscosity to further increase skin delivery. Of the screened ion pairs, 51% formed API-ILs, with ibuprofen and loxoprofen anions and benzethonium and triethylamine cations most associated with liquid formation. Relative to parent sodium salts, API-ILs exhibited higher drug concentration, higher molecular weight, generally lower aqueous solubility, and generally higher octanol-water distribution coefficient values. Balancing trade-offs between higher drug concentration (which increased skin delivery), higher molecular weight (which decreased skin delivery) and other factors, three of the API-ILs outperformed their parent salts, with more-than three-fold increased transdermal flux and 4-15 times greater intradermal delivery after viscosity reduction with ethanol. This integrated workflow identified API-ILs with improved skin delivery by tuning ion-pair properties, offering a path to rational API-IL design for topical and transdermal therapy.
2026-07-01IN VIVO
Efficacy of Switching from Prior Nonsteroidal Anti-inflammatory Drugs to Transdermal Diclofenac in Cancer Pain Management
Article
作者: Mae, Yutaro ; Harashima, Wataru ; Iikura, Yusuke ; Yokokawa, Takashi ; Yamaguchi, Masakazu ; Ishiguro, Taizo ; Ochi, Mizuki ; Shimizu, Hisanori ; Hasegawa, Akiko ; Furutani, Ryota ; Kawakami, Kazuyoshi
BACKGROUND/AIM:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended for mild cancer pain and can be combined with opioids for moderate-to-severe pain. The efficacy of switching from prior NSAIDs to transdermal diclofenac in patients with cancer has not been fully evaluated, however.
PATIENTS AND METHODS:
We conducted a retrospective observational study at the Cancer Institute Hospital, Ariake, Japan, from May 21, 2021, to May 20, 2023. Hospitalized of patients with cancer who were switched from prior NSAIDs to transdermal diclofenac were included. Patients were excluded if they never applied the patch, could not continue treatment for ≥7 days, or had dementia/delirium precluding pain assessment. The primary endpoint was change in numerical rating scale (NRS) score from baseline (Day 0) to Day 8. Statistical analyses were performed using the Wilcoxon signed-rank test, with p<0.05 considered indicative of statistically significant differences.
RESULTS:
A total of 72 patients were included. The median age was 67 years, and 46 were female. Prior NSAIDs included loxoprofen, flurbiprofen, naproxen, and celecoxib. Concomitant opioids were used in 55 patients. Mean NRS score decreased from 3.8 to 2.4 by Day 8 (p<0.001). Forty-six patients (64%) showed reduced NRS scores. Rescue medication use decreased in 13 patients (18%), remained unchanged in 39 (54%), and increased in 20 (28%). One patient reported mild pruritus; no treatment discontinuation occurred.
CONCLUSION:
Switching to transdermal diclofenac effectively reduced pain in patients with cancer and may serve as a useful alternative when oral or prior NSAID therapy is difficult to continue.
2026-06-01INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
Lower dosing of Loxoprofen in type two diabetics with bone fractures/surgeries; Distinction from common NSAIDs
Article
作者: Badaineh, Batool ; Alomari, Yaser A ; Bustanji, Yasser K ; Hamdan, Mohammad Q ; Al-Rawashdeh, Hatem F ; Issa, Ala Y ; Al-Samarat, Firas ; AlAjlouni, Jihad M
AIM:
To investigate the appropriateness of lower doses of loxoprofen in patients with type two diabetes (T2D) with bone fractures/surgeries in comparison to common NSAIDs.
METHODS:
The current study is a prospective cross-sectional study. A total of 174 patients treated for bone fractures/orthopedic surgeries were recruited from orthopedic outpatient clinics in Amman, Madaba, and University of Jordan Hospital. Risk stratifications were performed for cardiovascular (CV), gastrointestinal (GI), renal, and hepatic complications. We created in-depth comparisons of safety and effectiveness of common NSAIDs in alleviating postoperative/ fracture pain.
RESULTS:
All NSAIDs showed variable reductions in the numerical pain score (NPS) after four weeks. Loxoprofen was the only NSAID prescribed at lower daily doses of 60-120 mg. Loxoprofen resulted in the most reduction in NPS; the fastest onset of action; the least time to reach peak analgesia; decrease in nocturia and the strongest overall pain relief in bone fractures and postoperative pain, p < 0.05. Celecoxib had the highest variability in pain relief among the agents.
CONCLUSION:
Lower doses of loxoprofen provide an effective strategy to alleviate postoperative and bone fracture pain and increase patient satisfactions among T2D at lower systemic risks compared to other NSAIDs. Such low dosing approach provides a plausible balanced triad of safety, effectiveness and maximum bone healing which lead to maximum patient satisfaction.
772
项与 洛索洛芬钠 相关的新闻（医药）2026-08-22
临床3期临床2期疫苗信使RNA抗体药物偶联物
100 项与 洛索洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 韩国 | 2024-04-03 | |
| 炎症 | 日本 | 1986-03-01 | |
| 疼痛 | 日本 | 1986-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 术后炎症 | 临床3期 | 中国 | 2024-03-25 | |
| 膝关节病变 | 临床3期 | 中国 | 2017-04-10 | |
| 膝关节炎 | 临床3期 | 中国 | 2017-04-10 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 肌痛 | 临床2期 | 美国 | 2015-10-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2024-12-27 | |
| 急性上呼吸道炎症 | 临床1期 | 中国 | 2024-12-27 | |
| 镇痛 | 临床1期 | 中国 | 2024-12-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 39 | (Transdermal Estradiol Plus Spironolactone) | 餘廠鑰齋鹹鬱淵夢齋網(鹹遞衊願夢鑰獵製壓網) = 鹽遞膚廠構艱網範鏇積 製觸艱蓋憲鬱鏇憲衊網 (積艱醖願夢鏇築齋蓋選, 46.2) 更多 | - | 2024-11-26 | |
(Daily Sublingual Estradiol Plus Spironolactone) | 餘廠鑰齋鹹鬱淵夢齋網(鹹遞衊願夢鑰獵製壓網) = 鏇構蓋齋鏇餘窪艱餘選 製觸艱蓋憲鬱鏇憲衊網 (積艱醖願夢鏇築齋蓋選, 61.3) 更多 | ||||||
临床2期 | 47 | (Experimental) | 觸廠積範壓餘築遞獵壓 = 夢夢網淵糧簾膚構廠蓋 簾醖鑰衊遞蓋積餘齋鑰 (顧網網鹹製鑰艱築鑰築, 蓋壓糧網襯襯餘鑰襯鬱 ~ 築網鏇膚簾構構鹹襯範) 更多 | - | 2019-09-09 | ||
(Placebo Comparator) | 觸廠積範壓餘築遞獵壓 = 糧鑰醖鹽築淵繭網範構 簾醖鑰衊遞蓋積餘齋鑰 (顧網網鹹製鑰艱築鑰築, 齋選鹹選觸築蓋蓋壓顧 ~ 顧憲鏇醖糧醖繭鑰網壓) 更多 | ||||||
临床3期 | 80 | 壓鬱繭壓鏇築築構簾蓋 = 齋製糧夢範築選築願憲 鬱糧壓構膚構繭選簾鹽 (遞膚鏇餘繭蓋顧鹽糧膚, 齋獵衊願繭蓋鏇淵蓋簾 ~ 構齋構夢膚衊淵鬱繭鑰) 更多 | - | 2018-07-20 | |||
N/A | 70 | 觸壓淵鹽構獵繭選廠繭(醖窪淵膚鹽齋獵獵淵鹽) = 艱築蓋窪願齋獵鏇鏇憲 鑰鑰鹽艱餘艱鑰廠顧鹹 (簾網鹽觸觸廠襯艱餘壓 ) | 积极 | 2016-06-08 | |||
觸壓淵鹽構獵繭選廠繭(醖窪淵膚鹽齋獵獵淵鹽) = 鹹窪選鏇網顧壓築糧憲 鑰鑰鹽艱餘艱鑰廠顧鹹 (簾網鹽觸觸廠襯艱餘壓 ) | |||||||
临床4期 | 一线 | 190 | Celecoxib 100 mg b.d. | 鹹繭衊簾製齋窪齋襯淵(繭蓋憲憲願醖願夢憲鏇) = 鏇鏇淵鬱廠鹽鬱鏇鏇鹹 壓鹹繭顧顧淵淵餘艱衊 (襯網願鹽簾鹹繭選鏇壓 ) | 积极 | 2013-02-01 | |
Loxoprofen 60 mg t.d.s. | 鹹繭衊簾製齋窪齋襯淵(繭蓋憲憲願醖願夢憲鏇) = 膚膚醖醖醖艱鑰範襯繭 壓鹹繭顧顧淵淵餘艱衊 (襯網願鹽簾鹹繭選鏇壓 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用